Generic Name and Formulations:
Methenamine hippurate 1g; tabs; contains tartrazine.
Indications for HIPREX:
Prophylaxis and suppression of recurrent UTIs.
1g twice daily.
<6yrs: not recommended. ≥6yrs: 0.5–1g twice daily.
Renal or severe hepatic insufficiency. Severe dehydration.
Maintain acid urine. Monitor therapy and liver function with repeated urine cultures. Aspirin allergy. Elderly. Pregnancy.
Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Nausea, dysuria, rash, bladder irritation, albuminuria, hematuria, elevated transaminases.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|